Första Sidan / Källhänvisningar / Alzheimer´s disease, scientific references

Alzheimer´s disease, scientific references


Abalan F. Alzheimer's disease and malnutrition: A new etiological hypotheses. Med Hypotheses 1984; 15:385-93.

Abalan F, Delile JM. B12 deficiency in presenile dementia. Letter. Biol Psychiatry 1985; 20(11):1251.

Abalan F. Alzheimer's disease: The nutritional hypothesis. J Orthomol Med 1988; 3(1):13-17.

Adams JD Jr, Klaidman LK, Odunze IN, et al. Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide and vitamin E. Mol Chem Neuropathol 1991; 14:213-26.

Agbayewa MO, Bruce VM, Siemens V. Pyridoxine, ascorbic acid and thiamine in Alzheimer and comparison subjects. Can J Psychiatry 1992; 37(9):661-2.

Allegro L et al. Oral phosphatidylserine in elderly patients with cognitive deterioration. An open study. Clin Trials J 1987; 24:104-8.

Amaducci L et al. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study. Psychopharmacol Bull 1988; 24:130-4.

Amaducci L, Crook TH, Lippi A, et al. Use of phosphatidylserine in Alzheimer's disease. Ann N Y Acad Sci 1991; 640:245-9.

Baker GB, Reynolds GP. Biogenic amines and their metabolites in Alzheimer's disease: noradrenaline, 5- hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata. Neurosci Lett 1989; 100(1- 3):35-9.

Barabas J et al. Ascorbic acid in cerebrospinal fluid - a possible protection against free radicals in the brain. Arch Gerontol Geriatr 1995; 21:43-8.

Barak Y et al. Inositol treatment of Alzheimer's disease: a double-blind, cross-over placebo controlled trial. Prog Neuro-Psychopharmacol Biol Psychiatry 1996; 20:729-35.

Bartus R et al. Age related changes in passive avoidance retention: modulation with dietary choline. Science 1980; 209:301-3.

Basun H et al. Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects. J Neural Transm (P-D sect) 1990; 2:295-304.

Beal MF et al. Neurochemical characteristics of aluminum-induced neurofibrillary degeneration in rabbits. Neuroscience 1989; 29(2):339-46.

Behl C, Davis J, Cole G, et al. Vitamin E protects nerve cells from amyloid B protein toxicity. Biochem Biophys Res Commun 1992; 186:944-50.

Bell IR et al. Vitamin B12 and folate status in acute geropsychiatric patients: Affective and cognitive characteristics of a vitamin nondeficient population. Biol Psychiatry 1990; 27:125-37.

Bell IR, Edman JS, Miller J, et al. Relationship of normal serum vitamin B12 and folate levels to cognitive test performance in subtypes of geriatric major depression. J Geriatr Psychiatry Neurol 1990; 3(2):98-105.

Bellia JP et al. The role of silicic acid in the renal excretion of aluminium. Ann Clin Lab Sci 1996;26:227-33.

Beta-carotene said to protect against cognitive impairment. Medical Tribune September 5, 1996:17.

Birchall JD, Chappell JS. The chemistry of aluminium and silicon and Alzheimer's disease. Clin Chem 34:265-7, 1988.

Birchall JD, Chappell JS. Aluminium water chemistry and Alzheimer's disease. Lancet i:953, 1989.

Birchall JD. Dissolved silica and bioavailability of aluminium. Letter. Lancet 342:299, 1993.

Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 26 1996;(1):1-9.

Blass JP, Gleason P, Brush D, et al. Thiamine and Alzheimer's disease. A pilot study. Arch Neurol 1988; 45(8):833-5.

Bober MJ. Senile dementia and nutrition. Letter. Br Med J. 1984; 288:1234.

Bohnen N, Jolles J, Degenaar CP. Lower blood levels of vitamin B-12 are related to decreased performance of healthy subjects in the Stroop Color-Word Test. Neurosci Res Commun 11:53-6, 1992.

Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol 24:511-16, 1986.

Bottiglieri T, Godfrey P, Flynn T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53(12):1096-8, 1990.

Bowman BAB. Acetyl-carnitine and Alzheimer's disease. Nutr Rev 50(5):142-4, 1992.

Brinkman SD et al. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). Brief Reports 2:281-5, 1982.

Burnet FM. A possible role of zinc in the pathology of dementia. Lancet i:186-8, 1981.

Burns A, Holland T. Vitamin E deficiency. Letter. Lancet i:805-6, 1986.

Caffarra P, Santamaria V. The effects of phosphatidylserine in patients with mild cognitive decline. An open trial. Clin Trials J 24:109-14, 1987.

Calvani M, Carta A, Caruso G, et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. Ann N Y Acad Sci 663:483-6, 1992.

Candy JM et al. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet i:354-7, 1986.

Carmel R et al. Food cobalamin malabsorption occurs frequently in patients with unexplained low serum cobalamin levels. Arch Intern Med 148(8):1715-9, 1988.

Carta A, Calvani M. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease? Ann N Y Acad Sci 640:228-32, 1991.

Carta A, Calvani M, Bravi D, Chuachalla SN. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci 695:324-6, 1993.

Castano A, Cano J, Machado A. Low selenium diet affects monoamine turnover differentially in substantia nigra and striatum. J Neurochem 61:1302-7, 1993.

Cipolli C, Chiari G. Effects of L-acetylcarnitine on mental deterioration in the aged: initial results. Clin Ter 132:479-510, 1990.

Clausen J. Demential syndromes and the lipid metabolism. Acta Neurol Scand 70(5):345-55, 1984.

Glick JL. Dementias: the role of magnesium deficiency and an hypothesis concerning the pathogenesis of Alzheimer's disease. Med Hypotheses 31(3):211-25, 1990.

Cole MG, Prchal JF. Low serum B12 in Alzheimer-type dementia. Age Ageing 13:101-5, 1984.

Connor JR, Benkovic SA. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. Ann Neurol 32:34-44, 1992.

Constantinidis J. The hypothesis of zinc deficiency in the pathogenesis of neurofibrillary tangles. Med Hypotheses 35(4):319-23, 1991.

Corrigan FM et al. Aluminium and Alzheimer's disease. Letter. Lancet ii:268-9, 1989.

Corrigan FM, Van Rhijn AG, Ijomah G, et al. Tin and fatty acids in dementia. Prostaglandins Leukot Essent Fatty Acids 43(4):229-38, 1991.

Corrigan FM, Van Rhijn A, Horrobin DF. Essential fatty acids in Alzheimer's disease. Ann N Y Acad Sci 640:250-2, 1991.

Corrigan FM, Van Rhizn AG, Best PV, et al. Carnitine and acetyl-L-carnitine content of human hippocampus and erythrocytes in Alzheimer's disease. J Nutr Environ Med 5:35-9, 1995.

Cowburn JD, Blair JA. Aluminium chelator (transferrin) reverses biochemical deficiency in Alzheimer brain preparations. Letter. Lancet i:99, 1989.

Crellin R, Bottiglierei T, Reynolds EH. Folates and psychiatric disorders. Clinical potential. Drugs 45(5):623-36, 1993.

Cuajungco Math P, Lees GJ. Zinc and Alzheimer's disease: is there a direct link? Brain Res Rev 23:219-36, 1997.

Deary IJ, Hendrickson AE. Calcium and Alzheimer's disease. Letter. Lancet i:1219, 1986.

Deary IJ et al. Serum calcium levels in Alzheimer's disease: A finding and an aetiological hypothesis. Pers Individ Diff 8(1):75-80, 1987.

Deijen JB, van der Beek EJ, Orlebeke JF, van den Berg H. Vitamin B6 supplementation in elderly men. Effects on mood, memory, performance, and mental effort. Psychopharmacology 109:489-96, 1992.

De La Fourniere F et al. Vitamin B12 deficiency and dementia: a multicenter, epidemiologic and therapeutic study. Preliminary therapeutic trial. Semin Hop Paris 73(5-6):133-40, 1997.

Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M. Double-blind randomized controlled study of phosphatidylserine in senile demented patients. Acta Neurol Scand 73:136-40, 1986.

Durlach J. Magnesium depletion and pathogenesis of Alzheimer's disease. Letter. Magnes Res 3(3):217-8, 1990.

Dysken M. A review of recent clinical trials in the treatment of Alzheimer's dementia. Psychiatr Ann 17(3):178, 1987.

Ebrahim S. Aluminium and Alzheimers disease. Lancet I; 1989: 267.

Edwardson JA, Moore PB, Ferrier IN, et al. Effect of silicon on gastrointestinal absorption of aluminium. Lancet 342:211- 12, 1993.

Ehmann WD et al. Brain trace elements in Alzheimer's disease. Neurotoxicology 7:197-206, 1986.

Eisinger J, Arroyo P, Plantamura A, et al. Erythrocyte transketolase in Alzheimer's disease: the thiamin hypothesis. J Adv Med 7(2):69-75, 1994.

Enk C et al. Reversible dementia and neuropathy associated with folate deficiency 16 years after partial gastrectomy. Scand J Haematol 25(1):63-6, 1980.

Evans JR. Alzheimer's dementia: Some possible mechanisms related to vitamins, trace elements and minerals, suggesting a possible treatment. J Orthomol Med 1(4):249-54, 1987.

Evans JR. Alzheimers Disease and Vitamin-Mineral Status. Health of America, vol 5: 1987: 402.

Farrar G et al. Defective gallium-transferrin binding in Alzheimer disease and Down syndrome: possible mechanism for accumulation of aluminium in brain. Lancet 335:747-50, 1990.

Ferrier IN, Leake A, Taylor GA, et al. Reduced gastrointestinal absorption of calcium in dementia. Age Ageing 19(6):368-75, 1990.

Feussner JR, Durham VA Medical Center and Duke U. School of Medicine - presentation to the Southern Section of the Society for Research and Education in Primary Care Internal Medicine, USA, 1984.

Forbes WF, Hayward LM, Agwani N. Dementia, aluminium, and fluoride. Letter. Lancet 338:1592-3, 1991.

Foster HD. Health, Disease and the Environment. Boca Raton, CRC Press, 1992:311-16.

Frolich L, Riederer P. Fre radical mechanisms in dementia of the Alzheimers type and the potential for antioxidantive treatment. Drug Res 1995; 45: 443-446.

Fujita T. Aging and calcium as an environmental factor. J Nutr Sci Vitaminol (Tokyo) 31
Suppl S15-9, 1985.

Gaby AR. Townsend Letter for Doctors Feb.-March, 1989.

Gajdusek DC. Hypothesis: Interference with axonal transport of neurofilaments as a common pathogenic mechanism in certain diseases of the central nervous system. N Engl J Med 312:714-9, 1985.

Gale CR, Martyn CN, Cooper C. Cognitive impairment and mortality in a cohort of elderly people. BMJ 312:608-11, 1996.

Garruto RM et al. Low-calcium, high-aluminum diet-induced motor neuron pathology in cynomolgus monkeys. Acta Neuropathol (Berl) 78(2):210-9, 1989.

Garzya G, Corallo D, Flore A, et al. Evaluation of the effects of L-acetylcarnitine
on senile patients suffering from depression. Drugs Exp Clin Res 16:101-6, 1990.

Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45:836-40, 1988.

Glick JL. Dementias. The role of magnesium deficiency and hypothesis concerning the pathogenesis of Alzheimers disease. Med hypoth 1990; 31: 211-225.

Gold M, Chen MF, Johnson K. Plasma and red blood cell thiamine deficiency in patients with dementia of the Alzheimer's type. Arch Neurol 52(11):1081-6, 1995.

Good PF, Perl DP, Bierer LM et al. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann Neurol 31:286-92, 1992.

Goodman L Alzheimer's disease: a clinico-pathologic analysis of twenty-three cases with a theory of pathogenesis. J Nerv Ment Dis 118:97, 1953.

Goodman M et al. Are U.S. lower normal B12 limits too low? J Am Geriatr Soc 44(10):1274-5, 1996.

Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 249:2917-21, 1983.

Granata Q, DeMichele J. Phosphatidylserine in elderly patients. An open trial. Clin Trials J 24:99-103, 1987.

Grant WB. Dietary links to Alzheimer's disease. Alzheimer's Dis Rev 2:42-55, 1997.

Graves AB et al. The association between aluminum-containing products and Alzheimer's disease. J Clin Epidemiol 43(1):35-44, 1990.

Gross JS, Weinbraub NT, Neufeld RR, Libow LS. (Latent) pernicious anemia in the demented patient without anemia or macrocytosis: A case for early recognition. J Am Geriatr Soc 34(8):612-14, 1986.

Grossman L, Wunderlich S. Weight loss and malnutrition in Alzheimer's. Abstract. J Am Coll Nutr 14(5):546, 1995.

Growing evidence for aluminum/Alzheimer's link. Clin Psychiatry News, December, 1988, p. 2.

Guarnaschelli C, Fugazza G, Pistarine C. Pathological brain ageing: evaluation of the efficacy of a pharmacological aid. Drugs Exp Clin Res 14:715-18, 1988.

Hall GR. This hospital patient has Alzheimers. Am Journ of Nurs, Oct-1991.

Harrington CR, Wischik CM, McArthur FK, et al. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 343:993-7, 1994.

Hershey CO et al. Cerebrospinal fluid trace element content in dementia: Clinical, radiologic, and pathologic correlations. Neurology 33(10):1350-3, 1983.

Hershey CO et al. Trace element content of brain in Alzheimer's disease and aging. Trace Elem Med 2:40-3, 1985.

Hoffer A. Vitamin B-3: niacin and its amide. Townsend Letter, October, 1995:30-39.

Holmes JM. Cerebral manifestations of vitamin B12 deficiency. Br Med J 1956; ii:1394-8.

Howard JMH. Clinical import of small increases in serum aluminum. Clin Chem 30(10):1722-3, 1984.

Hronek J et al. Zinc - serum levels in dementia. Act Nerv Super (Praha) 31(2):125-6, 1989.

Hughes JT. Aluminium Encephalopathy and Alzheimers disease. Letter Lancet 1989; I: 490-91.

Hullin RP. Serum zinc in psychiatric patients. Prog Clin Biol Res 129:197-206, 1983.

Ikeda T et al. Vitamin B12 levels in serum and cerebrospinal fluid of people with
Alzheimer's disease. Acta Psychiatr Scand 1990;82(4):327-9.

Ikeda T, Yamamoto K, Takahashi K, et al. Treatment of Alzheimer-type dementia with intravenous mecobalamin. Clin Ther 14(3):426-37, 1992.

Inada M et al. Cobalamin contents of the brains in some critical and pathologic states. Int J Vitam Nutr Res 1982;52(4):423-9.

Jackson JA et al. Aluminum from a coffee pot. Letter. Lancet i:781-2, 1989.

Jackson CVE et al. Vitamin E and Alzheimer's disease in subjects with Down's syndrome. J Ment Def Res 32:479- 84, 1988.

Jacqmin H, Commenges D, Letenneur L, et al. Components of drinking water and risk of cognitive impairment in the elderly. Am J Epidemiol 1994; 139(1):48-57.

Jacqmin-Gadda H, Commenges D, Letenneur L, et al. Silica and aluminum in drinking water and cognitive impairment in the elderly. Epidemiology 1996; 7(3):281-5.

Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci 52(2):M76-M79, 1997.

Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145(1):33-41, 1997.

Kanof P. Red blood cell choline. Biol Psychiatry 20:375-83, 1985.

Karnaze DS, Carmel R. Low serum cobalamin levels in primary degenerative dementia. Do some patients harbor atypical cobalamin deficiency states? Arch Intern Med 147(3):429-31, 1987.

Karnaze DS, Carmel R. Neurologic and evoked potential abnormalities in subtle cobalamin deficiency states, including deficiency without anemia and with normal absorption of
free cobalamin. Arch Neurol 47(9):1008-12, 1990.

King RG. Do raised aluminum levels in Alzheimer's dementia contribute to cholinergic neuronal deficits? Med Hypotheses 14(3):301-6, 1984.

Kobayashi S, Fjuiwara S, Arimoto S, et al. Hair aluminum in normal aged and senile dementia of Alzheimer type. Prog Clin Biol Res 1989; 317:1095-109.

Larsson M, Semb H, Winblad B, Amberla K, Wahlund L-O: Odor identification in normal aging and early Alzheimer’s disease: effects of retrieval support. Neuropsychology 1999; 13:47-53.

Lehmann J et al. Tryptophan malabsorption in dementia. Improvement in certain cases after tryptophan therapy as indicated by mental behaviour and blood analysis. Acta Psychiatr Scand 64(2):123-31, 1981.

Lehmann A et al. Taurine and neuronal resistance to hypoxia. FEBS Lett 233(2):437-9, 1988.

Lemke MR. Plasma magnesium decrease and altered calcium/magnesium ratio in severe dementia of the Alzheimer type. Biol Psychiatry 37:341-3, 1995.

Lammi UK et al. Mental disability among elderly men in Finland: prevalence,
predictors and correlates. Acta Psychiatr Scand 80(5):459-68, 1989.

Levitt A, Karlinsky L. Folate, vitamin B12, and cognitive impairment in patients with Alzheimer's disease. Acta Psychiatr Scand 86:301-5, 1992.

Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318(26):1720-8, 1988.

Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's Disease. J Neurol Neurosurg Psychiatry 48:736-42, 1985.

Martin DC. B12 and folate deficiency dementia. Clin Geriatr Med 4(4):841-52, 1988; Strachan RW, Henderson JG. Dementia and folate deficiency. Quart J Med 36:189-204, 1967.

Martin DC et al. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc 40(2):168-72, 1992.

Martyn CN et al. Geographical relation between Alzheimer's disease and aluminium in drinking water. Lancet i:59-62, 1989.

Martyn CN et al. Aluminum concentrations in drinking water and risk of Alzheimer's disease. Epidemiology 8(3):281-86, 1997.

Mastrogiacomo F et al. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann Neurol 39:585-91, 1996.

McCaddon A, Kelly C. Familial Alzheimer's disease and vitamin B12 deficiency. Age Aging 23:334-7, 1994.

McLachlan DR et al. Aluminum and neurodegenerative disease: Therapeutic implications. Am J Kidney Dis 6(5):322-9, 1985.

McLachlan DRC et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337:1304-8, 1991.

Meador K, Loring D, Nichols M, et al. Preliminary findings of high-dose thiamine in dementia of Alzheimer's type. J Geriatr Psychiatry Neurol 6(4):222-9, 1993.

Meador KJ, Nichols ME, Franke P, et al. Evidence for a central cholinergic effect of high-dose thiamine. Ann Neurol 34(5):724-6, 1993.

Melamed E et al. Reversible central nervous system dysfunction in folate deficiency. J Neurol Sci 25:93-8, 1975.

Mena I. Manganese, in F Bronner, JW Coburn, Eds. Disorders of Mineral Metabolism. I. Trace Minerals. New York, Academic Press, 1981:233-70.

Meydani M et al. Effect of vitamin E, selenium and age on lipid peroxidation events in rat cerebrum. Nutr Res 5:1227-36, 1985.

Miller BL et al. Differences in red blood cell choline and lipid-bound choline between patients with Alzheimer's disease and control subjects. Neurobiol Aging 12:61-4, 1991.

Muller D et al. Vitamin E in brains of patients with Alzheimer's disease and Down's
syndrome. Lancet i:1093-4, 1986.

Nachev PC, Larner AJ. Zinc and Alzheimer's disease. Trace Elem Electrolytes 13(2):55-9, 1996.

Neri LC, Hewitt D. Aluminium, Alzheimer's disease, and drinking water. Letter. Lancet 338:390, 1991.

Nicklowitz WJ, Mandybur TI. Neurofibrillary changes following childhood lead encephalopathy. J Neuropathol Exp Neurol 34:445-55, 1975.

Nijst TQ, Wevers RA, Schoonderwaldt HC, et al. Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 53(11):951-4, 1990.

Nolan CR, CeGoes JJ, Alfrey AC et al. Aluminium and lead absorbtion from dietary sources in women ingestium calcium citrate. Southern Med J 1994; 97: 894-898.

Ogihara T, Miya K, Morimoto S. Possible participation of calcium-regulating
factors in senile dementia in elderly female subjects. Gerontology 36 Suppl 1:25-30, 1990.

Olivieri G, et al. Mercury Induces Cell Cytotoxicity and Oxidative Stress and Increases ß-Amyloid Secretion and Tau Phosphorylation in SHSY5Y Neuroblastoma Cells. Journal of Neurochemistry 2000; 74(1): 231-236.

Ortega RM, Manas LR, Andres P, et al. Functional and psychic deterioration in elderly people may be aggravated by folate deficiency. J Nutr 126:1992-9, 1996.

Pajonk F-G, Kessler H, Supprian T et al, Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. Journal of Alzheimer's Disease 2005;8(1):23-27.

Palmieri G et al. Double-blind controlled trial of phosphatidylserine in patients with senile mental deterioration. Clin Trials J 24:73-83, 1987.

Passeri M, Chcinotta D, Bonati PA, et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res 10(1-2):75-9, 1990.

Pavlova GA. Content of amino acids, ionized forms of calcium and acetylcholinesterase in the cerebral cortex in senile dementia. Zh Nevropatol Psikhiatr 84(7):1012-6, 1984.

Perl DP, Brody AR. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208:297-9, 1980.

Perl DP. Relationship of aluminum to Alzheimer's disease. Environ Health Perspect 63:149-53, 1985.

Perl DP, Good PF. Uptake of aluminum into central nervous system along nasal-olfactory pathways. Lancet i:1028, 1987.

Perry EK, Perry RH. New insights into the nature of senile (Alzheimer-type) plaques. Trends Neurosci. 8:301-3, 1985.

Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 83(8):2758-62, 1986.

Peterson C, Ratan RR, Shelanski ML, Goldman JE. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 83(20):7999-8001, 1986.

Pettegrew JW, Klunk WE, et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 16(1):1-4, 1995.

Pomara N et al. Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry 149(2):251-4, 1992.

Prior RL, Crim MC, Castaneda C, et al. Conditions altering plasma concentrations of urea cycle and other amino acids in elderly human subjects. J Am Coll Nutr 15(3):237-47, 1996.

Puca FM et al. Exploratory trial of phosphatidylserine efficacy in mildly demented subjects. Clin Trials J 24:94-8, 1987.

Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 11(10):638-47, 1990.

Ratfy AK et al. IRCS J Med Sci 14:815, 1986.

Rappaport EM. Achlorhydria: Associated symptoms and response to hydrochloric acid. N Engl J Med 252(19):802-5, 1955.

Regland B, Gottfries CG, Oreland L, Svennerholm L. Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study. Acta Psychiatr Scand 78(4):451-7, 1988.

Regland B - presentation to the European College of Neuropsychopharmacology - reported in Clin Psychiatry News, Sep., 1989.

Regland B, Gottfries CG, Oreland L. Vitamin B12-induced reduction of platelet monamine oxidase activity in patients with dementia and pernicious anemia. Eur Arch Psychiatry Clin Neurosci 240(4-5):288-91, 1991.

Regland B, Abrahamsson L, Blennow K, et al. Vitamin B12 in CSF/serum B12 ratio in demented men. Acta Neurol Scand 85(4):276-81, 1992.

Repasy A et al. Utility of routine vitamin B12 levels in the workup of dementia. Abstract. Psychogeriatrics Dec. 1987, pp. 32-3.

Reynolds EH et al. S-adenosylmethionine and Alzheimer's disease. Abstract. Neurology 39 (Suppl 1):397, 1989.

Rezai-Zadeh K, Shytle D, Sun N et al. Green Tea Epigallocatechin-3-Gallate (EGCG) Modulates Amyloid Precursor Protein Cleavage and Reduces Cerebral Amyloidosis in Alzheimer Transgenic Mice. The Journal of Neuroscience, 2005, 25(38):8807-8814;

Riggs KM, Sprio A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 63:306-14, 1996.

Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF. Relation between aluminum concentrations in drinking water and Alzheimer's disease: an 8-year follow-up study. Am J Epidemiol. 2000;152(1):59-66.

Rondeau V, Jacqmin-Gadda H, Commenges D, et al. Aluminum and Silica in Drinking Water and the Risk of Alzheimer's Disease or Cognitive Decline: Findings From 15-Year Follow-up of the PAQUID Cohort. Am J Epidemiol 2009;169:489-96.

Russell R, Human Nutritional Research Center on Aging at Tufts U., Boston. Food & Nutrition Briefs, U.S. Department of Agriculture, July-Sept., 1991.

Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res 20(4):169-76, 1994.

Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49(11):1137-41.

Sano M, Ernesto C, Thomas RG, et al. A Controlled Trial of Selegiline, Alpha Tocopherol, or Both as treatment for Alzheimers Disease. NEJM 1997;336(17):1216-22.

Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991;41(11):1726-32.

Sapira JD, Tullis S, Mallaly R. Reversible dementia due to folate deficiency. South Med J 68:776-8, 1975.

Schorah CJ et al. Plasma vitamin C concentrations in patients in a psychiatric hospital. Hum Nutr Clin Nutr 37C:447-52, 1983.

Schurr A et al. Taurine improves the recovery of neuronal function following cerebral hypoxia: An in vitro study. Life Sci 40(21):2059-66, 1987.

Schurr A et al. Glutamine protects neuronal function against cerebral hypoxia: A study using the in vitro hippocampal slice preparation. Brain Res 412(1):179-81, 1987.

Scileppi KP, Blass JP, Baker HG. Circulating vitamins in Alzheimer's dementia as compared to other dementias. J Am Geriatr Soc 32(10):709-11, 1984.

Seshadri et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New England Journal of Medicine 2002; 346: 476-83.

Shaw DM, Tidmarsh SF, Sweeney EA, et al. Pilot study of amino acids in senile dementia. Br J Psychiatry 139:580, 1981.

Shaw DM et al. Senile dementia and nutrition. Letter. Br Med J [Clin Res] 288:792- 3, 1984.

Sheu KFR, Clarke DD, Kim YT, et al. Studies of transketolase abnormality in Alzheimer's disease. Arch Neurol 48:81-3, 1991.

Shin RW. Interaction of aluminium with paired helical filament tau is involved in neurofibrially pathology of Alzheimers disease. Gerontol 1997; 43(suppl 1): 16-23.

Shore D et al. Hair and serum copper, zinc, calcium and magnesium concentrations in Alzheimer-type dementia. J Am Geriatr Soc 32(12):892-5, 1984.

Shovon SD et al. The neuropsychiatry of megaloblastic anaemia. Br Med J 281:1036-8, 1980.

Simonoff M et al. Serum and erythrocyte selenium in normal and pathological states in France. Trace Elem Med 5:64-9, 1988.

Sinforiani E et al. Cognitive decline in ageing brain: therapeutic approach with phosphatidylserine. Clin Trials J 24:115-24, 1987.

Sinforiani E, Iannuccelli M, Mauri M, et al. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. Int J Clin Pharmacol Res 10(1-2):69-74, 1990.

Sneath P, Chanarin I, Hodkinson MH, et al. Folate status in a geriatric population and its relation to dementia. Age Ageing 2:177-82, 1973.

Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26(6):421-5, 1991.

Sommer BR, Wolkowitz OM. RBC folic acid levels and cognitive performance in elderly patients: a preliminary report. Biol Psychiatry 24:352-4, 1988.

Spivak JL, Jackson DL. Pellagra: an analysis of 18 patients and a review of the literature. Johns Hopkins Med J 140(6):295-309, 1977.

Strachan RW, Henderson JG. Dementia and folate deficiency. Quart J Med 36:189-204, 1967.

Subhash MN, Padmashree TS, Srinivas KN, et al. Calcium and phosphorus levels in serum and CSF in dementia. Neurobiol Aging 12(4):267-9, 1991.

Sullivan K. The evidence linking silver-mercury fillings to Alzheimer's disease: a literature review. Townsend Letter for Doctors & Patients. August/Sept., 1997:74-83.

Sylverster PE. Ageing in the mentally retarded, in J Dobbing et al., Eds. Scientific Studies in Mental Retardation. London, Macmillian, for the Royal Society of Medicine, 1984:259-77.

Teunisse S et al. Dementia and subnormal levels of vitamin B12: Effects of replacement therapy on dementia. J Neurol 243:522-9, 1996.

Thal LJ, Carta A, Clarke WR, et al. A 1-year multicenter placebo-controlled study of
acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 47:705-11, 1996.

Thomas DE et al. Tryptophan and nutritional status of patients with senile dementia. Psychol Med 16(2):297-305, 1986.

Torizumi K et al. [Relationship between parathyroid hormone and magnesium in sera of dementia patients. Radioisotopes 37(4):203-8, 1988.

Tully CL et al. Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun study. Aging 13:6(16):2105-8, 1995.

Walton J et al. Uptake of trace amounts of aluminium into the brain from drinking water. Neurotoxicology 1995; 16: 187-190.

Watkins SE et al.Plasma amino acids in patients with senile dementia and in subjects with Down's syndrome at an age vulnerable to Alzheimer changes. J Ment Defic Res 33:159-66, 1989.

Vance DE et al. Trace element imbalances in hair and nails of Alzheimer's disease patients. Neurotoxicology 9(2):197-208, 1988.

van Tiggelen CJM. Alzheimer's disease/alcohol dementia: Association with zinc
deficiency and cerebral vitamin B12 deficiency. J Orthomol Psychiatry 13(2):97-104, 1984.

Ward NI, Mason JA. Neutron activation analysis techniques for identifying elemental
status in Alzheimer's disease. J Radioanalyt Nucl Chem 113(2):515- 26, 1987.

Warsama JJ, Launer LJ, Witterman JEM, et al. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam study. Am J Epidemiol 144:275-9, 1996.

Weintraub S et al. Lecithin in the treatment of Alzheimer's disease. Arch Neurol 40:527, 1983.

Wenk GL, Stemmer KL. Suboptimal dietary zinc intake increases aluminium accumulation into the rat brain. Brain Res 288:393-5, 1983.

Wenstrup D, Ehmann WD, Markesbery WR. Trace element imbalances in isolated subcellular fractions of Alzheimer's disease brains. Brain Res 533(1):125-31, 1990.

West RD. Aluminosilicates and Alzheimer's disease. Letter. Lancet ii:682, 1985.

Villardita C et al. Multicentre clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration. Clin Trials J 24:84-93, 1987.

Wisniewski KE et al. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17:270- 82, 1985.

Wisniewski HM et al. Aluminum chloride induced neurofibrillary changes in the developing rabbit. A chronic animal model. Ann Neurol 8(5):479-90, 1980. Aluminum, chemical physiology, and Alzheimer's disease. Lancet ii:1008-10, 1988.

Yasui M et al. Role of zinc in the central nervous system, in Mineral and Medical Neurotoxicology. CRC Press, 1997:139-45.

Zaman Z, Roche S, Fielden P, et al. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 21:91-4, 1992.

Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements. Arch Neurol 2004;61:82–8.

Zapatero MD, Garcia de Jalon A, Pascual F et al. Serum aluminium levels in Alzheimers disease and other senile dementias. Bio Trace Element Res 1995; 47: 235-240.

Zhang L, Fiala M, Cashman J et al. Curcuminoids enhance amyloid-ß uptake by macrophages of Alzheimer’s disease patients. Journal of Alzheimer's Disease 2006:10:1-7.


Letar du efter ett Shop-produkt kan du söka det här: